ESTEVE Acquires Regis Technologies

Aceto Acquires IsleChem to Add U.S. Manufacturing and R&D Capabilities

December 21, 2020

Manufacturing

Aceto U.S., LLC has acquired IsleChem, a Grand Island, New York-based chemical manufacturer and contract R&D provider. The acquisition adds U.S. manufacturing, analytical and R&D capabilities to Aceto’s global specialty-chemicals sourcing and distribution platform and supports expansion of IsleChem’s facility and workforce.

Astorg Acquires Pharmaceutical CDMO CordenPharma from ICIG

May 2, 2022

Pharmaceuticals

Astorg has signed a binding agreement to acquire CordenPharma, a global contract development and manufacturing organization (CDMO) focused on APIs, excipients and drug products, from International Chemical Investors Group (ICIG). CordenPharma employs over 2,600 people across 11 manufacturing sites and an R&D laboratory in Europe and the US; the founders will reinvest alongside Astorg. The transaction is subject to customary regulatory approvals and terms were not disclosed.

ESTEVE Acquires HRA Pharma Rare Diseases from Perrigo

May 14, 2025

Pharmaceuticals

Barcelona-based ESTEVE completed the acquisition of HRA Pharma Rare Diseases (the rare-diseases business previously held by Perrigo) in July 2024, in a divestiture transaction announced by Perrigo for up to €275 million. The deal expands ESTEVE's rare-disease portfolio and strengthens its presence in Europe and the United States while supporting the company’s strategic focus on highly specialized therapies.

Formosa Laboratories Acquires SynChem to Expand North American CDMO Footprint

June 3, 2024

Pharmaceuticals

Formosa Laboratories, Inc., a Taiwan-based API supplier and CDMO, has completed its acquisition of SynChem, Inc., a contract research laboratory in suburban Chicago. SynChem will operate as SynChem-Formosa with Dr. W. Paul Mar remaining as CEO as the combined operations expand Formosa's US CDMO capabilities for small-molecule APIs and ADC-related chemistries.

Recro Pharma Acquires IRISYS (San Diego)

August 13, 2021

Pharmaceuticals

Recro Pharma (NASDAQ: REPH) acquired San Diego–based CDMO IRISYS for approximately $49.85 million in cash, stock and a seller promissory note, transforming Recro into a bi‑coastal, full‑service CDMO. The acquisition expands Recro's capabilities (including aseptic fill/finish and lyophilization), diversifies its client base and adds near‑term revenue and backlog.

Avista Capital Partners Invests in eMolecules

March 25, 2021

Healthcare Services

Avista Capital Partners has signed a definitive agreement to invest in eMolecules, a San Diego–based e-procurement and marketplace platform for high-value chemicals and bioreagents used in drug discovery. Financial terms were not disclosed; Avista said the investment will support eMolecules' growth and expansion into additional biopharma and academic customers.